InspireMD (NYSE: NSPR) has incurred losses consistently over the past several years. Of late, shareholders have been apprehensive about their investments as
No surprises expected when InspireMD (NSPR) reports Q4 earnings
Categories
Health Care
Bio-Path Holdings (NASDAQ: BPTH): 2019 Earnings Snapshot
-- Bio-Path Holdings Inc. (NASDAQ: BPTH) reported a loss of $3.24 share for the full year 2019, narrower than a loss of
Aurinia Pharmaceuticals (NASDAQ: AUPH): Q4 2019 Earnings Snapshot
-- Aurinia Pharmaceuticals (NASDAQ: AUPH) reported a fourth-quarter 2019 loss of $0.78 per share versus a loss of $0.14 per share expected.
Stock Analysis: GW Pharma (GWPH) offers irresistible upside potential
For GW Pharmaceuticals (NASDAQ: GWPH), the main growth strategy for the current fiscal year is to expand its product pipeline beyond Epidiolex,
Arbutus Biopharma (ABUS): FY19 Earnings Snapshot
-- Arbutus Biopharma Corporation (NASDAQ:ABUS) reported a net loss of $164.9 million or $2.89 per share for fiscal 2019, compared to a
BioCryst Pharmaceuticals (BCRX) Q4 2019 Earnings Snapshot
-- BioCryst Pharmaceuticals (NASDAQ: BCRX) reported a loss of $0.02 per share for the fourth quarter of 2019 vs. expected loss of
AMAG Pharmaceuticals (AMAG) Q4 2019 Earnings Snapshot
-- AMAG Pharmaceuticals (NASDAQ: AMAG) reported a net loss of $199.9 million or $5.89 per share for the fourth quarter of 2019
Tilray Inc (NASDAQ: TLRY) Q4 2019 Earnings Call Transcript
Tilray Inc (NASDAQ: TLRY) Q4 2019 Earnings Conference Call Final Transcript Corporate Participants: Brendan Kennedy -- Chairman, President and Chief Executive Officer Mark Castaneda -- Chief Financial
Amicus Therapeutics (FOLD): FY 2019 Earnings Snapshot
-- Biotechnology company Amicus Therapeutics (NASDAQ: FOLD) reported a net loss of $356.4 million or $1.48 per share for fiscal 2019, compared
Eagle Pharmaceuticals (NASDAQ: EGRX): Q4 2019 Earnings Snapshot
-- Eagle Pharmaceuticals Inc. (NASDAQ: EGRX) reported its fourth-quarter 2019 adjusted earnings of $0.48 per share versus $0.46 per share expected. --
Cara Therapeutics Inc. (NASDAQ: CARA) Q4 2019 Earnings Call Transcript
Cara Therapeutics Inc (NASDAQ: CARA) Q4 2019 Earnings Conference Call Final Transcript Corporate participants: Jack Hildick-Smith -- Investor Relations Derek Chalmers -- President, Director and Chief Executive
SmileDirectClub (SDC) stock drops to lowest since IPO amid growth prospects
Shares of SmileDirectClub Inc. (NASDAQ: SDC) plunged over 52% to $7.17 on Thursday, which is the lowest since the initial public offering
Sage Therapeutics (SAGE) Q4 2019 Earnings Snapshot
-- Sage Therapeutics (NASDAQ: SAGE) reported fourth quarter 2019 loss of $3.25 per share vs. expected loss per share of $3.61. --
ACADIA Pharmaceuticals (ACAD): Q4 2019 Earnings Snapshot
-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) reported Q4 2019 loss of $0.34 per share, vs. $0.36 expected. -- Revenue grew 65% to
Sarepta Therapeutics (SRPT): Q4 2019 Earnings Snapshot
-- Sarepta Therapeutics, Inc. (NASDAQ: SRPT) reported a loss of $1.57 per share in the fourth quarter of 2019, vs $1.86 per share loss expected.
Moderna (MRNA) ships coronavirus vaccine candidate for trials, shares hit a peak
Shares of Moderna Inc. (NASDAQ: MRNA) soared to a record high of $29.98 on Wednesday after shipping the first coronavirus vaccine candidate
Endo International (NASDAQ: ENDP): Q4 2019 Earnings Snapshot
-- Endo International plc (NASDAQ: ENDP) reported its fourth-quarter 2019 adjusted earnings of $0.74 per share versus $0.57 per share expected. --
Amarin Corporation (AMRN): Q4 2019 Earnings Snapshot
— Amarin Corporation plc (NASDAQ: AMRN) reported earnings of $0.04 per share in the fourth-quarter 2019 vs. $0.02 per share loss expected. — Revenue grew
GW Pharma (GWPH) Q4 loss narrows on strong sales; set to launch Epidiolex in Europe
GW Pharmaceuticals (NASDAQ: GWPH) reported a narrower net loss for the fourth quarter of 2019 as net sales rose sharply, with strong
MannKind Corporation (MNKD): Q4 2019 Earnings Snapshot
-- MannKind Corporation (NASDAQ: MNKD) reported Q4 2019 loss of $0.07 per share, vs. a loss of $0.07 expected. -- Total revenue
Intercept Pharmaceuticals (NASDAQ: ICPT): Q4 2019 Earnings Snapshot
-- Intercept Pharmaceuticals (NASDAQ: ICPT) reported a fourth-quarter 2019 loss of $2.99 per share versus a loss of $2.67 per share expected.